Hospital
Delaware Valley Hospital, INC
Delaware Valley Hospital, INC was paid $9.45M by Medicaid between Jan 2018 and Nov 2024, across 140 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 24% of everything it billed.
33Billing provider infoDELAWARE VALLEY HOSPITAL, INC
WALTON, NY 13856
WALTON, NY 13856
33aNPI1417940719assigned 08/23/2005
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$9.45M
24GClaims96,157
24DCodes billed140
24AFirst – last monthJan 2018 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 222 | $9K | |
| 2019 | 4,951 | $321K | |
| 2020 | 12,050 | $824K | |
| 2021 | 16,218 | $1.24M | |
| 2022 | 17,208 | $3.27M | |
| 2023 | 23,252 | $2.23M | |
| 2024incomplete | 22,256 | $1.56M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 24% | 16,367 | 14,357 | $2.30M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 4,642 | 4,396 | $1.26M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 9.5% | 5,615 | 5,062 | $899K |
| 80053 | Comprehensive metabolic panel | 6.3% | 5,776 | 5,222 | $598K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.5% | 3,675 | 1,298 | $520K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.7% | 2,560 | 2,498 | $439K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.5% | 3,307 | 2,848 | $422K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.6% | 1,630 | 1,550 | $341K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.9% | 1,460 | 1,401 | $276K |
| 36415 | Collection of venous blood by venipuncture | 2.8% | 6,814 | 6,054 | $267K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.9% | 965 | 900 | $179K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.7% | 2,088 | 1,993 | $164K |
128 more codes
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.5% | 581 | $146K |
| 99441 | 1.3% | 638 | $124K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.2% | 2,317 | $114K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 5,740 | $112K |
| 99442 | 1.1% | 495 | $103K | |
| 80061 | Lipid panel | 1.1% | 1,708 | $100K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 906 | $92K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 812 | $69K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 285 | $55K |
| 90837 | Psychotherapy session, about an hour | <1% | 323 | $53K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 268 | $52K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 143 | $50K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 165 | $42K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 486 | $41K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 65 | $40K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 380 | $39K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 562 | $38K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 260 | $33K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 601 | $33K |
| 84439 | <1% | 739 | $29K | |
| 90686 | <1% | 782 | $24K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 831 | $22K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,276 | $21K |
| 97161 | <1% | 102 | $21K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 994 | $16K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 44 | $16K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 28 | $16K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 50 | $16K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 148 | $14K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 71 | $13K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 97 | $13K |
| 81025 | <1% | 257 | $13K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 33 | $12K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 967 | $12K |
| 87631 | <1% | 133 | $11K | |
| 85027 | <1% | 427 | $10K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 81 | $10K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 116 | $9K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 37 | $9K |
| 85610 | <1% | 395 | $8K | |
| 81003 | <1% | 2,172 | $7K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 67 | $7K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 17 | $7K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 30 | $6K |
| 99173 | <1% | 126 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 716 | $5K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 73 | $5K |
| 82607 | <1% | 69 | $5K | |
| 36416 | <1% | 176 | $5K | |
| 90734 | <1% | 147 | $5K | |
| 86140 | <1% | 303 | $5K | |
| 90715 | <1% | 109 | $4K | |
| 99205 | Prolong outpt/office vis | <1% | 24 | $4K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 17 | $4K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 81 | $3K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 16 | $3K |
| 83735 | <1% | 200 | $3K | |
| 85652 | <1% | 186 | $2K | |
| 90656 | <1% | 89 | $2K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 305 | $2K |
| Q3014 | Telehealth originating site facility fee | <1% | 316 | $2K |
| 0012A | <1% | 65 | $2K | |
| 87070 | <1% | 208 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 931 | $2K |
| 83690 | <1% | 492 | $2K | |
| 81001 | <1% | 264 | $2K | |
| 0011A | <1% | 56 | $2K | |
| 0064A | <1% | 39 | $1K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 47 | $1K |
| 87581 | <1% | 33 | $1K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 16 | $1K |
| 90651 | <1% | 25 | $1K | |
| 87634 | <1% | 14 | $1K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 12 | $1K |
| 86803 | <1% | 25 | $1K | |
| 80050 | General health panel | <1% | 13 | $1K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 30 | $1K |
| 82150 | <1% | 174 | $1K | |
| 84702 | <1% | 24 | $996.45 | |
| 87486 | <1% | 34 | $985.74 | |
| 83721 | <1% | 29 | $909.01 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 103 | $874.76 |
| 85379 | <1% | 78 | $815.01 | |
| 92551 | <1% | 13 | $805.48 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 342 | $802.79 |
| 82728 | <1% | 13 | $796.24 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 1,701 | $653.09 |
| 85730 | <1% | 217 | $620.91 | |
| 87081 | <1% | 31 | $534.00 | |
| 87400 | <1% | 270 | $478.59 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 712 | $463.70 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 13 | $452.95 |
| 90682 | <1% | 19 | $382.69 | |
| 97010 | <1% | 20 | $339.41 | |
| 84484 | <1% | 364 | $333.51 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 506 | $303.17 |
| 87040 | <1% | 13 | $291.75 | |
| 85651 | <1% | 12 | $287.42 | |
| 73630 | <1% | 15 | $285.00 | |
| 83540 | <1% | 12 | $265.13 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $250.98 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 776 | $225.87 |
| 73564 | <1% | 12 | $188.56 | |
| 87420 | <1% | 127 | $178.46 | |
| 73610 | <1% | 12 | $147.79 | |
| A4221 | Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately) | <1% | 333 | $131.48 |
| 93000 | <1% | 473 | $112.18 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 391 | $23.74 |
| A4223 | Infusion supplies not used with external infusion pump, per cassette or bag (list drugs separately) | <1% | 151 | $17.98 |
| A4222 | Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately) | <1% | 61 | $8.28 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 431 | $6.44 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 72 | $3.75 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 512 | $3.63 |
| A4657 | Syringe, with or without needle, each | <1% | 223 | $1.40 |
| A4215 | Needle, sterile, any size, each | <1% | 143 | $1.34 |
| A4556 | Electrodes, (e.g., apnea monitor), per pair | <1% | 107 | $1.13 |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 205 | $0.76 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 127 | $0.21 |
| S1015 | Iv tubing extension set | 0% | 187 | $0.00 |
| 94664 | 0% | 13 | $0.00 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 13 | $0.00 |
| 90461 | 0% | 14 | $0.00 | |
| 83605 | 0% | 15 | $0.00 | |
| 82962 | 0% | 119 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 63 | $0.00 |
| 71045 | Radiologic examination, chest; single view | 0% | 48 | $0.00 |
| 94760 | 0% | 39 | $0.00 | |
| 82553 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOJO, ROLLAND (PRESIDENT/CEO)
| Provider | Location | Paid |
|---|---|---|
| Delaware Valley Hospital, INC | Walton, NY | $193K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.